Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-18, Stock:LLY, The news for the past five days is as follows:
2018-05-11: NEWS1: An Ear To The Pharma: 8 Stocks To Watch (VYGR, BOLD, RXII, CYADâ€¦).NEWS2: An Ear To The Pharma: 8 Stocks To Watch (VYGR, BOLD, RXII, CYADâ€¦).NEWS3: Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally..NEWS4: [$$] Eli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 Billion.NEWS5: Lilly to Participate in UBS Global Healthcare Conference.NEWS6: Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss.NEWS7: Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss.NEWS8: Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down.NEWS9: Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down.NEWS10: Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates.NEWS11: Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates.NEWS12: How Teva Performed in 1Q18.NEWS13: Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates.NEWS14: Label Expansion May Boost Keytruda’s Revenue Prospects in 2018.NEWS15: Keytruda Continues to Be Major Growth Driver for Merck in 2018.
2018-05-14: NEWS1: Health Care Sector Update for 05/14/2018: TNDM,AMPH,LLY,ATNX.NEWS2: Health Care Sector Update for 05/14/2018: TNDM,AMPH,LLY,ATNX.NEWS3: Health Care Sector Update for 05/14/2018: AMPH,LLY,ATNX.NEWS4: Health Care Sector Update for 05/14/2018: AMPH,LLY,ATNX.NEWS5: Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y.NEWS6: Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y.NEWS7: Ex-Dividend Reminder: Eli Lilly, Amgen and Simon Property Group.NEWS8: Ex-Dividend Reminder: Eli Lilly, Amgen and Simon Property Group.NEWS9: WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders.NEWS10: Lilly to buy cancer drug developer AurKa Pharma.NEWS11: Eli Lilly to buy cancer drug developer AurKa Pharma.NEWS12: Lilly to Acquire AurKa Pharma.NEWS13: Eli Lilly Takes $7M Gamble On Global Health Working... In Indiana.NEWS14: Lilly To Buy AurKa Pharma.NEWS15: Lilly To Buy AurKa Pharma.
2018-05-15: NEWS1: MEIP Gets Funded, PFNX Riding High, GNPX Turns Heads.NEWS2: MEIP Gets Funded, PFNX Riding High, GNPX Turns Heads.NEWS3: Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline.NEWS4: Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline.NEWS5: Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline.NEWS6: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for May 16, 2018.NEWS7: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for May 16, 2018.NEWS8: An Update on Teva’s Highly Anticipated Migraine Drug.NEWS9: Star Kleiner Perkins VC may be launching her own firm.NEWS10: An Overview of Valeant Pharmaceuticals’ Performance in 1Q18.NEWS11: Eli Lilly's cluster-headache treatment passes phase 3 test.NEWS12: Eli Lilly's cluster-headache treatment passes phase 3 test.NEWS13: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache.NEWS14: Lilly's migraine drug meets main goal in cluster headache trial.NEWS15: Eli Lilly: Galcanezumab Meets Primary Endpoint In Phase 3 Study - Quick Facts.NEWS16: Eli Lilly: Galcanezumab Meets Primary Endpoint In Phase 3 Study - Quick Facts.
2018-05-16: NEWS1: Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care.NEWS2: Eli Lilly's Cluster Headache Candidate Succeeds in Phase III.NEWS3: Eli Lilly's Cluster Headache Candidate Succeeds in Phase III.NEWS4: iShares Core High Dividend ETF Experiences Big Outflow.NEWS5: iShares Core High Dividend ETF Experiences Big Outflow.NEWS6: Eli Lilly&apos;s Cluster Headache Candidate Succeeds in Phase III.NEWS7: LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim.NEWS8: LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim.
2018-05-17: NEWS1: U.S. FDA approves Amgen migraine drug, price set at $6900/yr.NEWS2: Roche Tecentriq Combo Achieves Longer Overall Survival Rate.NEWS3: Roche Tecentriq Combo Achieves Longer Overall Survival Rate.NEWS4: Exelixis Is Expected to Report a Robust Revenue Rise in 2018.NEWS5: Teva’s Fiscal Guidance: Confidence in Its Growth.NEWS6: Wired News – Eli Lilly’s Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache.

Answer: Rise